Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,226 stopped studies mapped to Malignant Genitourinary System Neoplasm and descendants · 88% state a reason
Over the 2,226 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | May 6, 2022 | Fusion Pharmaceuticals Inc. | Fusion announced that it is discontinuing this study as part of a portfolio prioritization and… | Sponsor / business decision |
| NCT03837353 | A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With… | Phase 1 / Phase 2 | terminated | Feb 12, 2019 | NYU Langone Health | Terminated early due to slow accrual in the context of changing practice patterns. | Enrollment / accrual |
| NCT00250016 | Pharmacology Study of Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin (L9NC) | — | withdrawn | Nov 7, 2005 | University of New Mexico | UNM did not proceed with research | Other (stated, no rule matched) |
| NCT04341740 | Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma(WindMIL-001) | N/A | terminated | Apr 10, 2020 | University of Oklahoma | Study funding was withdrawn. | Funding |
| NCT03338712 | Micro-RNA Expression Profiles in Localised Prostate Cancer | — | withdrawn | Nov 9, 2017 | Wuerzburg University Hospital | Principal Investigators no longer in business | Sponsor / business decision |
| NCT05425862 | Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate…(REPAIR) | Phase 1 | suspended | Jun 21, 2022 | Peter MacCallum Cancer Centre, Australia | Enrolment suspended to further assess supplementary non-clinical study data. | Enrollment / accrual |
| NCT06159998 | New Markers for Treatment Response to Radiotherapy in Prostate Cancer | — | withdrawn | Dec 7, 2023 | University of Basel | Study closed | Other (stated, no rule matched) |
| NCT02649673 | LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and… | Phase 1 | terminated | Jan 7, 2016 | SCRI Development Innovations, LLC | Clinical program was discontinued by Novartis | Other (stated, no rule matched) |
| NCT02887248 | Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or… | Phase 2 | terminated | Sep 2, 2016 | SCRI Development Innovations, LLC | Enrollment issues | Enrollment / accrual |
| NCT03861403 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus… | Phase 1 | terminated | Mar 4, 2019 | Leap Therapeutics, Inc. | Product development discontinued unrelated to safety. | Safety / toxicity |
| NCT03641287 | The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer… | N/A | terminated | Aug 22, 2018 | University of Washington | Enrollment ended early due to the funding timeline | Enrollment / accrual |
| NCT03694834 | Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer | Early Phase 1 | terminated | Oct 3, 2018 | UNC Lineberger Comprehensive Cancer Center | Slow accrual | Enrollment / accrual |
| NCT01215136 | First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced… | Phase 2 | terminated | Oct 6, 2010 | Matthew Galsky | Lack of Accrual | Enrollment / accrual |
| NCT03412630 | Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With… | N/A | terminated | Jan 26, 2018 | ECOG-ACRIN Cancer Research Group | poor accrual | Enrollment / accrual |
| NCT03550040 | 3D Versus Robot Assisted Laparoscopic Prostatectomy. | N/A | terminated | Jun 8, 2018 | Tampere University Hospital | accrual was sufficient at interim analysis to draw final conclusions needed to publish | Efficacy / futility |
| NCT03735589 | Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells)… | Phase 1 / Phase 2 | withdrawn | Nov 8, 2018 | Roswell Park Cancer Institute | new study to be created | Other (stated, no rule matched) |
| NCT05998941 | A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the… | Phase 2 | withdrawn | Aug 21, 2023 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Slow progress in development, the sponsor decided to withdraw and no longer proceed. | Sponsor / business decision |
| NCT03944902 | CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer…(BRCA) | Phase 1 | terminated | May 10, 2019 | University of Alabama at Birmingham | will not resume. company choosing not to continue with drug. one participant now off study. | Sponsor / business decision |
| NCT04555603 | Axitinib Therapy Management Study | — | withdrawn | Sep 18, 2020 | Pfizer | Failed at data quality assurance process before any analyses would be performed | Other (stated, no rule matched) |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine… | Phase 1 | withdrawn | Oct 26, 2020 | QuantumLeap Healthcare Collaborative | Study withdrawn as scientific interest in pursuing the SYD985+Paclitaxel combination has diminished. | Other (stated, no rule matched) |
| NCT02432690 | A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation | Phase 2 | terminated | May 4, 2015 | Sumitomo Pharma America, Inc. | not stated | Not stated |
| NCT05910697 | Clinical Utility of MyProstateScore 2.0 P2 | N/A | terminated | Jun 20, 2023 | Qure Healthcare, LLC | The decision to stop the study was made by the sponsor, based solely on timeline constraints. | Other (stated, no rule matched) |
| NCT02232646 | A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies | Phase 2 | withdrawn | Sep 5, 2014 | Sumitomo Pharma America, Inc. | Low feasibility | Other (stated, no rule matched) |
| NCT05454371 | Investigation of Urinary Biomarkers for the Detection of Prostate Cancer(URODETECT-WP2) | N/A | withdrawn | Jul 12, 2022 | Novosanis NV | Study is part of PhD trajectory and currently the trajectory is in the final phases without the… | Enrollment / accrual |
| NCT06050954 | A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder…(CARMA) | Phase 2 | withdrawn | Sep 22, 2023 | Fox Chase Cancer Center | Change in standard of care. | Other (stated, no rule matched) |
| NCT05905341 | Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in… | Phase 1 | withdrawn | Jun 15, 2023 | Pfizer | This decision was based on business considerations and not due to specific safety reasons or a… | Safety / toxicity |
| NCT02834975 | Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial… | Phase 2 | terminated | Jul 15, 2016 | University of Miami | Investigator left institution | Investigator |
| NCT05332483 | Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer(MA-EEC) | Phase 1 | terminated | Apr 18, 2022 | Sunnybrook Health Sciences Centre | Slow enrollment | Enrollment / accrual |
| NCT05405439 | To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in… | Phase 1 / Phase 2 | terminated | Jun 6, 2022 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | The sponsor voluntarily terminated the study | Other (stated, no rule matched) |
| NCT05712941 | Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients… | Phase 3 | withdrawn | Feb 6, 2023 | EQRx International, Inc. | The study is being closed based on corporate changes at EQRx and is not related to any efficacy or… | Safety / toxicity |
| NCT04054752 | Vaccine Response With NT-I7 | Phase 1 | withdrawn | Aug 13, 2019 | National Cancer Institute (NCI) | No subjects enrolled. | Enrollment / accrual |
| NCT03619655 | Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of… | Phase 1 | terminated | Aug 8, 2018 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Due to changing prostate cancer standard of care, the research question became obsolete as the… | Other (stated, no rule matched) |
| NCT05120622 | Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High…(Rideau) | Phase 1 / Phase 2 | withdrawn | Nov 15, 2021 | University of British Columbia | Withdrawal of funding | Funding |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous… | Phase 3 | terminated | May 9, 2013 | Pfizer | Per recommendation of the DMC, enrollment into the study was discontinued in April 2016 after the… | Efficacy / futility |
| NCT04300140 | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or… | Phase 1 / Phase 2 | terminated | Mar 9, 2020 | Aravive, Inc. | Due to business reasons | Sponsor / business decision |
| NCT04729608 | Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With…(AXLerate-OC) | Phase 3 | terminated | Jan 28, 2021 | Aravive, Inc. | There were no significant differences in median PFS between batiraxcept + paclitaxel or paclitaxel… | Safety / toxicity |
| NCT00496756 | Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer | Phase 2 | terminated | Jul 4, 2007 | University of Nebraska | Low accrual rate | Enrollment / accrual |
| NCT01041027 | Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk… | Phase 2 | terminated | Dec 30, 2009 | Albert Einstein College of Medicine | Due to slow accrual. Results from the PORTEC3 the study rendered the hypothesis no longer valid. | Enrollment / accrual |
| NCT03649841 | Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron… | Phase 2 | terminated | Aug 28, 2018 | University of Washington | Terminated due to low accrual. | Enrollment / accrual |
| NCT05329545 | Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)(UP-NEXT) | Phase 3 | terminated | Apr 15, 2022 | Mersana Therapeutics | Study Terminated by Sponsor | Other (stated, no rule matched) |
| NCT03824808 | Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic… | Phase 4 | terminated | Jan 31, 2019 | University of Missouri-Columbia | Challenges with recruitment of surgical research subjects in the target population. | Enrollment / accrual |
| NCT00180739 | Safety Trial of Magnetic Resonance (MR) Guided Focused Ultrasound Surgery (FUS) in Women… | Phase 4 | withdrawn | Sep 16, 2005 | Imperial College London | Recruitment not possible worldwide | Enrollment / accrual |
| NCT02626377 | Multicenter Prospective Cohort of Informal Caregivers in Burgundy and Franche-Comté(ICE) | N/A | terminated | Dec 10, 2015 | Centre Hospitalier Universitaire de Besancon | inclusions problems | Other (stated, no rule matched) |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With… | Phase 1 / Phase 2 | withdrawn | Oct 19, 2023 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT03623490 | Optimizing the Management of Patients With Oral Therapy(IPAC) | N/A | terminated | Aug 9, 2018 | Centre Georges Francois Leclerc | Following an insufficient recruitment, the sponsor decided to halt prematurely inclusions | Enrollment / accrual |
| NCT05466916 | EDITS Pilot Study for Gynecologic Cancer Survivors | N/A | withdrawn | Jul 20, 2022 | Rutgers, The State University of New Jersey | Study was never initiated and no participants were enrolled. | Enrollment / accrual |
| NCT03180398 | Multi-parametric Magnetic Resonance Imaging for Prostate Cancer Patients | N/A | terminated | Jun 8, 2017 | Henry Ford Health System | PI left institution | Investigator |
| NCT04598321 | BrUOG 390: Neoadjuvant Treatment With Talazoparib | Phase 1 | terminated | Oct 22, 2020 | Brown University | termination of research grant agreement | Other (stated, no rule matched) |
| NCT04511026 | Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in… | Phase 2 | terminated | Aug 12, 2020 | Stanford University | Efficacy | Efficacy / futility |
| NCT04907968 | Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With…(UPGRADE) | Phase 1 | terminated | Jun 1, 2021 | Mersana Therapeutics | Study Terminated by Sponsor | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Dec 19, 2023source: clinicaltrials